Calypte Biomedical to Host 2nd Quarter Conference Call
August 10 2004 - 11:21AM
PR Newswire (US)
Calypte Biomedical to Host 2nd Quarter Conference Call PLEASANTON,
Calif., Aug. 10 /PRNewswire-FirstCall/ -- Calypte Biomedical
Corporation (OTC:CYPT) (BULLETIN BOARD: CYPT) announced today that
it will host a conference call on Thursday August 12th 2004, at
11:00 a.m. EDT. The call will outline the results of the second
quarter and six months ended June 30, 2004. Dial in numbers for the
conference call are as follows. Investors in the U.S. and Canada
interested in participating in the conference call may dial
800-435-1261 and reference the Calypte Biomedical call.
International investors may dial 617-614-4076. A live webcast of
the conference call including a slide presentation will be
available for investors by accessing the Company's website at
http://www.calypte.com/ and clicking on "Investors." A replay will
be available through August 24, 2004 by calling 888-286-8010.
International callers should dial 617-801-6888 for the replay. The
replay confirmation code is 60270956. About Calypte Biomedical:
Calypte Biomedical Corporation, headquartered in Pleasanton,
California, is a public healthcare company dedicated to the
development and commercialization of in vitro diagnostic tests,
primarily for the detection of antibodies to Human Immunodeficiency
Virus (HIV), and other sexually transmitted and infectious
diseases. Calypte's currently marketed laboratory- based tests
include an enzyme immunoassay (EIA) HIV-1 antibody screening test
and an HIV-1 antibody western blot supplemental test, the only two
FDA-approved HIV-1 antibody tests for use on urine samples, as well
as an FDA-approved serum HIV-1 antibody western blot supplemental
test. Calypte is actively engaged in developing new test products
for the rapid detection of HIV and other infectious diseases.
Calypte believes that there is a significant need for rapid
detection of such diseases globally to control their proliferation,
particularly in lesser-developed countries, which lack the medical
infrastructure to support laboratory-based testing. Calypte
believes that testing for HIV and other infectious diseases may
make important contributions to public health. Company Contact:
Investor Relations Contact: Richard Brounstein, CFO Tim Clemensen,
(925) 730-7200 Rubenstein Investor Relations Email: Phone:
212-843-9337 Email: DATASOURCE: Calypte Biomedical Corporation
CONTACT: Company Contact - Richard Brounstein, CFO of Calypte
Biomedical Corporation, +1-925-730-7200, ; Investor Relations
Contact - Tim Clemensen of Rubenstein Investor Relations,
+1-212-843-9337, , for Calypte Biomedical Corporation Web site:
http://www.calypte.com/
Copyright